[1]刘美玲.噻托溴铵吸入剂结合布地奈德福莫特罗治疗COPD的效果及对血氧饱和度的影响[J].医学信息,2024,37(21):138-141.[doi:10.3969/j.issn.1006-1959.2024.21.032]
　LIU Meiling.Effect of Tiotropium Bromide Powder for Inhalation Combined with Budesonide and Formoterol Fumarate in the Treatment of COPD and its Effect on Blood Oxygen Saturation[J].Journal of Medical Information,2024,37(21):138-141.[doi:10.3969/j.issn.1006-1959.2024.21.032]
点击复制

噻托溴铵吸入剂结合布地奈德福莫特罗治疗COPD的效果及对血氧饱和度的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年21期
页码:
138-141
栏目:
药物与临床
出版日期:
2024-11-01

文章信息/Info

Title:
Effect of Tiotropium Bromide Powder for Inhalation Combined with Budesonide and Formoterol Fumarate in the Treatment of COPD and its Effect on Blood Oxygen Saturation
文章编号:
1006-1959（2024）21-0138-04
作者:
刘美玲
上栗县人民医院呼吸内科，江西 上栗 337009
Author(s):
LIU Meiling
Department of Respiratory Medicine,Shangli County People’s Hospital,Shangli 337009,Jiangxi,China
关键词:
COPD; 噻托溴铵吸入剂; 布地奈德福莫特罗; 血氧饱和度
Keywords:
COPD; Tiotropium bromide powder for inhalation; Budesonide and formoterol fumarate; Blood oxygen saturation
分类号:
R563.9
DOI:
10.3969/j.issn.1006-1959.2024.21.032
文献标志码:
A
摘要:
目的 研究慢性阻塞性肺疾病（COPD）患者使用噻托溴铵吸入剂结合布地奈德福莫特罗治疗的效果，以及对血氧饱和度的影响。方法 选取2021年3月-2023年3月在我院诊治的68例COPD患者为研究对象，采用随机数字表法分为对照组（n=34）和观察组（n=34），对照组采用噻托溴铵吸入剂治疗，观察组在对照组基础上给予布地奈德福莫特罗治疗，比较两组治疗效果、血气指标[动脉血氧分压（PaO2）、动脉血二氧化碳分压（PaCO2）、血氧饱和度（SaO2）]、肺功能指标[第1秒用力呼气容积（FEV1）、用力肺活量（FVC）、第1秒用力呼气容积占预计值百分（FEV1%）]、呼吸困难程度评分、不良反应发生率。结果 观察组治疗总有效率为94.12%，高于对照组的82.35%（P＜0.05）；两组PaO2、SaO2均高于治疗前，PaCO2低于治疗前，且观察组PaO2、SaO2高于对照组，PaCO2低于对照组（P＜0.05）；两组FEV1、FVC、FEV1%均高于治疗前，且观察组高于对照组（P＜0.05）；两组MMRC评分均低于治疗前，且观察组低于对照组（P＜0.05）；观察组不良反应发生率为8.82%，与对照组的5.88%比较，差异无统计学意义（P＞0.05）。结论 噻托溴铵吸入剂结合布地奈德福莫特罗治疗COPD具有确切的效果，可提高治疗效果，改善肺功能、血氧饱和度，减轻呼吸困难，且不增加不良反应，是一种可行、有效、安全的治疗方案。
Abstract:
Objective To study the therapeutic effect of tiotropium bromide powder for inhalation combined with budesonide and formoterol fumarate in patients with chronic obstructive pulmonary disease (COPD) and its effect on blood oxygen saturation.Methods A total of 68 patients with COPD diagnosed and treated in our hospital from March 2021 to March 2023 were selected as the research objects. They were divided into control group (n=34) and observation group (n=34) by random number table method. The control group was treated with tiotropium bromide powder for inhalation, and the observation group was treated with budesonide and formoterol fumarate on the basis of the control group. The therapeutic effect, blood gas indexes [arterial partial pressure of oxygen (PaO2), arterial partial pressure of carbon dioxide (PaCO2), blood oxygen saturation (SaO2)], lung function indexes [forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), percentage of forced expiratory volume in the first second to predicted value (FEV1%)], dyspnea score and incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 94.12%, which was higher than 82.35% in the control group (P<0.05). PaO2 and SaO2 in the two groups were higher than those before treatment, PaCO2 was lower than that before treatment, and PaO2 and SaO2 in the observation group were higher than those in the control group, PaCO2 was lower than that in the control group (P<0.05). The FEV1, FVC and FEV1% of the two groups were higher than those before treatment, and those in the observation group were higher than those in the control group (P<0.05). The MMRC score of the two groups was lower than that before treatment, and that in the observation group was lower than that in the control group (P<0.05). The incidence of adverse reactions in the observation group was 8.82%, which was compared with 5.88% in the control group, the difference was not statistically significant (P>0.05).Conclusion Tiotropium bromide powder for inhalation combined with budesonide and formoterol fumarate has a definite effect in the treatment of COPD, which can improve the therapeutic effect, improve lung function and blood oxygen saturation, reduce dyspnea, and does not increase adverse reactions. It is a feasible, effective and safe treatment plan.

参考文献/References:

[1]孙田霞.噻托溴铵粉雾剂联合布地奈德福莫特罗粉吸入剂对COPD稳定期患者的疗效[J].河南医学研究,2020,29(15):2806-2807.[2]宋卫珍,董凌云.噻托溴铵吸入剂联合布地奈德福莫特罗治疗对老年急性加重期COPD患者肺功能及对HMGB1、Copeptin的影响[J].中国老年学杂志,2020,40(9):1847-1851.[3]张艳.噻托溴铵联合布地奈德福莫特罗治疗慢性阻塞性肺疾病临床研究[J].基层医学论坛,2023,10(8):11-13.[4]曹晓.噻托溴铵喷雾剂联合布地奈德福莫特罗粉吸入剂对支气管哮喘急性发作患者肺功能及生活质量的影响[J].河南医学研究,2019,28(15):2766-2768.[5]中国老年医学学会呼吸病学分会慢性阻塞性肺疾病学组.中国老年慢性阻塞性肺疾病临床诊治实践指南[J].中华结核和呼吸杂志,2020,43(2):110-119.[6]朱华源.布地奈德福莫特罗联合噻托溴铵对改善中重度稳定期慢性阻塞性肺疾病患者肺功能的临床观察[J].吉林医学,2019,62(1):89-90.[7]吴丽燕.布地奈德福莫特罗吸入剂和噻托溴铵吸入治疗老年慢性阻塞性肺疾病的临床研究[J].中国药物与临床,2019,19(18):3146-3148.[8]胡姗姗,田凡清,杨贵丽,等.布地奈德福莫特罗粉吸入剂联合噻托溴铵喷雾剂对COPD急性加重期患者肺功能及血清MMP-9、TIMP-1水平的影响[J].中国地方病防治杂志,2019,34(4):452,454.[9]孙茜,柴明思,齐秀芳.布地奈德福莫特罗联合噻托溴铵吸入剂治疗慢阻肺的疗效及对CRP、SaO2、pH水平影响[J].医学信息,2023,15(5):38-39.[10]房亮,尹忠文,雒谌龙,等.布地奈德福莫特罗粉吸入治疗肺癌合并慢性阻塞性肺疾病患者的临床疗效[J].慢性病学杂志,2019,20(3):444-445,448.[11]李方方,张高峰.噻托溴铵+信必可都保治疗慢阻肺的有效性及对患者运动耐力的影响[J].贵州医药,2021,45(9):1396-1397.[12]齐亚丽,李婷,池燕.噻托溴铵干粉吸入联合多索茶碱对重症支气管哮喘合并呼吸衰竭患者血气指标及血清超敏C反应蛋白、肿瘤坏死因子α水平影响[J].创伤与急危重病医学,2021,9(5):400-402,405.[13]王宁,栗娜,韩巧玲,等.布地奈德福莫特罗联合噻托溴铵治疗哮喘-慢性阻塞性肺疾病重叠的临床研究[J].中国综合临床,2021,37(1):39-45.[14]李少雄,王维建.噻托溴铵治疗慢性阻塞性肺疾病并发重度支气管哮喘的效果[J].深圳中西医结合杂志,2021,31(9):197-198.[15]邓翔,周雄平,蒋在慧,等.噻托溴铵对老年COPD稳定期患者肺功能、血气参数和炎症因子的影响[J].海南医学院学报,2018,24(22):1951-1953,1958.[16]王娜,许恩喜,陈昕晟,等.噻托溴铵、布地奈德/福莫特罗与异丙托溴铵治疗慢性阻塞性肺疾病的临床疗效和药物经济学评价[J].湖北科技学院学报,2020,34(5):405-408.[17]刁鑫,贾艳云,潘双,等.吸烟慢性阻塞性肺疾病患者EOS、CRP、MUC5AC水平变化与肺功能的关系[J].疑难病杂志,2022,21(4):377-382.[18]张琼.布地奈德福莫特罗吸入治疗成人哮喘合并慢性阻塞性肺疾病临床效果观察[J].山西医药杂志,2021,50(17):2556-2558.[19]赵瑞芬,李霞,杨亚萍,等.噻托溴铵联布地奈德/福莫特群的影响[J].心肺血管病杂志,2018,37(2):98-102.

相似文献/References:

[1]马建娟.布地奈德联合异丙托溴铵雾化治疗COPD 急性加重期的效果评价[J].医学信息,2018,31(07):141.[doi:10.3969/j.issn.1006-1959.2018.07.048]
　MA Jian-juan.Efficacy Evaluation of Budesonide Combined with Ipratropium Bromide in Treatment of Acute Exacerbation of COPD[J].Journal of Medical Information,2018,31(21):141.[doi:10.3969/j.issn.1006-1959.2018.07.048]
[2]任庆玲.聚焦解决模式对慢阻肺患者主要照顾者的 照顾负担及负性情绪影响的研究[J].医学信息,2018,31(07):162.[doi:10.3969/j.issn.1006-1959.2018.07.057]
　REN Qing-ling.Study on the Effect of Focus-resolving Model on the Burden of Care and Negative Emotions of Primary Caregivers in Patients with Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(21):162.[doi:10.3969/j.issn.1006-1959.2018.07.057]
[3]刘 颖,杨志高,李慧琼,等.肠内联合肠外营养与肠内营养支持治疗COPD机械通气患者疗效比较的Meta分析[J].医学信息,2022,35(10):98.[doi:10.3969/j.issn.1006-1959.2022.10.024]
　LIU Ying,YANG Zhi-gao,LI Hui-qiong,et al.Meta-analysis of the Efficacy of Enteral Combined Parenteral Nutrition and Enteral Nutrition Support in the Treatment of COPD Patients with Mechanical Ventilation[J].Journal of Medical Information,2022,35(21):98.[doi:10.3969/j.issn.1006-1959.2022.10.024]
[4]刘怡彤,马利军.基于“互联网+”的移动医疗技术在慢性阻塞性肺病稳定期管理的应用及问题研究[J].医学信息,2019,32(06):38.[doi:10.3969/j.issn.1006-1959.2019.06.014]
　LIU Yi-tong,MA Li-jun.Application and Problem Research of Mobile Medical Technology Based on"Internet +"in Stable Period Management of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2019,32(21):38.[doi:10.3969/j.issn.1006-1959.2019.06.014]
[5]林 杨,苏志强,鲍 靖,等.ICF核心分类联合mMRC用于COPD患者康复效果的研究[J].医学信息,2019,32(03):175.[doi:10.3969/j.issn.1006-1959.2019.03.060]
　LIN Yang,SU Zhi-qiang,BAO Jing,et al.Effect of ICF Core Classification Combined with mMRC on Rehabilitation of COPD Patients[J].Journal of Medical Information,2019,32(21):175.[doi:10.3969/j.issn.1006-1959.2019.03.060]
[6]梁雪梅,蔡晓玉,王 真,等.综合护理措施对无创呼吸机治疗COPD合并呼吸衰竭的Meta分析[J].医学信息,2019,32(05):91.[doi:10.3969/j.issn.1006-1959.2019.05.027]
　LIANG Xue-mei,CAI Xiao-yu,WANG Zhen,et al.Meta-analysis of Comprehensive Nursing Measures for Non-invasive Ventilator in the Treatment of COPD with Respiratory Failure[J].Journal of Medical Information,2019,32(21):91.[doi:10.3969/j.issn.1006-1959.2019.05.027]
[7]吴 鹏,徐 超,曲 红.线性周期化训练和非线性周期化训练对慢性阻塞性肺疾病患者的影响[J].医学信息,2019,32(09):88.[doi:10.3969/j.issn.1006-1959.2019.09.028]
　WU Peng,XU Chao,QU Hong.Effects of Linear Periodic Training and Nonlinear Periodic Training on Patients with Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2019,32(21):88.[doi:10.3969/j.issn.1006-1959.2019.09.028]
[8]马宏境,刘 彬.慢性阻塞性肺疾病发病机制的研究[J].医学信息,2019,32(10):50.[doi:10.3969/j.issn.1006-1959.2019.10.018]
　MA Hong-jing,LIU Bin.Study on the Pathogenesis of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2019,32(21):50.[doi:10.3969/j.issn.1006-1959.2019.10.018]
[9]高小燕,陈 蓉,卢慧宇.血糖控制水平对COPD伴2型糖尿病患者 肺功能及其预后的影响[J].医学信息,2019,32(16):76.[doi:10.3969/j.issn.1006-1959.2019.16.023]
　GAO Xiao-yan,CHEN Rong,LU Hui-yu.Effect of Blood Glucose Control Level on Pulmonary Function and Prognosis in Patients with COPD and Type 2 Diabetes[J].Journal of Medical Information,2019,32(21):76.[doi:10.3969/j.issn.1006-1959.2019.16.023]
[10]聂 志.吸入用沙丁胺醇联合布地奈德对COPD急性加重期的作用[J].医学信息,2019,32(22):105.[doi:10.3969/j.issn.1006-1959.2019.22.033]
　NIE Zhi.Effect of Inhaled Salbutamol Combined with Budesonide on Acute Exacerbation of COPD[J].Journal of Medical Information,2019,32(21):105.[doi:10.3969/j.issn.1006-1959.2019.22.033]

更新日期/Last Update: 1900-01-01